Cardiac Biotech Solutions, Inc. (CBSC) Signs Exclusive 5-Year Distribution Agreement with Noventis Medical Covering Costa Rica, Panama, Colombia, and Argentina

Rhea-AI Summary

Cardiac Biotech Solutions (OTCID: CBSC) has secured a five-year exclusive distribution agreement with Noventis Medical for its cardiac monitoring products in Costa Rica, Panama, Colombia, and Argentina. The contract is valued at $600,000 USD and includes a right of first refusal for future distribution opportunities in other Central and South American countries.

The agreement centers on CBSC's MyCardia AT event monitoring platform, which combines wearable technology with AWS Cloud connectivity and mobile applications. The company has already obtained regulatory clearance in the U.S. and is pursuing additional approvals in Canada and China as part of its global expansion strategy.

Positive

• Secured $600,000 USD distribution agreement for Latin American markets
• Obtained exclusive distribution rights in four key countries for 5 years
• Right of first refusal for additional Central and South American markets
• Product already has U.S. regulatory clearance with Canada and China submissions in progress

Negative

• None.

LAS VEGAS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products, today announced the execution of a new distribution agreement with Noventis Medical, granting the Company five-year exclusive rights to distribute CBSC’s products across Costa Rica, Panama, Colombia, and Argentina.

Under the terms of the agreement, Noventis Medical has committed to a total of $600,000 USD contract value for the distribution rights. In addition, the Company has granted Noventis a right of first refusal for any future distribution opportunities across other Central and South American countries, provided it can match the terms offered by other prospective partners.

“We are delighted to expand our international presence through this new strategic partnership with Noventis Medical,” said Charles Martin, Chief Executive Officer of CBSC. “This agreement strengthens our reach into key Latin American markets and, we believe, provides a solid foundation for additional regional expansion. We also believe that the right of first refusal provision also ensures that our long-term collaboration with Noventis can grow in step with future opportunities across Central and South America.”

John Quam, President of Noventis Medical stated, “Noventis Medical is very excited to collaborate with CBSC and its product, MyCardia AT, to bring a reliable solution for identifying heart issues in the Latin American market. Cardiovascular disease remains the leading cause of death in the region, and this technology provides doctors with early insights so they can address problems and keep patients healthier for longer. We are committed to working alongside the medical community to deliver innovative tools that truly make a difference.”

The Company continues to advance global commercialization of its MyCardia AT event monitoring platform, which integrates lightweight, easy-to-use wearable technology with AWS Cloud-based connectivity and mobile applications for iOS, Android, and WeChat. With regulatory clearance already secured in the U.S. and additional submissions progressing in Canada and China, CBSC’s newest international agreement represents another milestone in its mission to provide state-of-the-art cardiac monitoring solutions worldwide.

As additional new developments occur, Cardiac Biotech Solutions, Inc. will make timely announcements through press releases and regulatory filings to keep its shareholders, industry participants, and the public markets informed.

About Cardiac Biotech Solutions, Inc.:
Cardiac Biotech Solutions, Inc., through its international subsidiaries, provides innovative products and services in the ambulatory non-invasive cardiac monitoring space. Our electrocardiogram (EKG) devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms provide improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians.

Company Contact Information:
Telephone: (888) 225-0870
Investor Inquiries: investor@cardiacbiotech.com
Follow CBSC: Twitter, Facebook, Instagram, LinkedIn, YouTube, and Newsletter

This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions, and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties, including, without limitation, the ability to obtain financing and regulatory and shareholder approval for anticipated actions.

FAQ

What is the value of CBSC's distribution agreement with Noventis Medical?

The distribution agreement is valued at $600,000 USD for exclusive rights to distribute CBSC's products in Costa Rica, Panama, Colombia, and Argentina over five years.

Which countries are included in CBSC's new distribution agreement?

The agreement covers four Latin American countries: Costa Rica, Panama, Colombia, and Argentina.

What is MyCardia AT and where has it received regulatory approval?

MyCardia AT is an event monitoring platform that combines wearable technology with AWS Cloud connectivity and mobile applications. It has received regulatory clearance in the United States, with pending submissions in Canada and China.

What special rights does Noventis Medical have for future CBSC distribution opportunities?

Noventis Medical has a right of first refusal for any future distribution opportunities in other Central and South American countries, provided they can match terms offered by other prospective partners.

How long is CBSC's distribution agreement with Noventis Medical?

The distribution agreement with Noventis Medical is for a period of five years.